BCC Stock Recent News

BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company (NYSE: BCC) will host a webcast and conference call to discuss 2025 first quarter earnings on Tuesday, May 6, 2025, at 9:30 a.m. Eastern. To join the webcast, go to the Investors section of our website at www.bc.com/investors and select the Event Calendar link. Analysts and investors who wish to ask questions during the Q&A session can register for the call here. The archived webcast will be available in the Investors section of Boise Cas.

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd.

BCC, AFLYY and HUN have been added to the Zacks Rank #5 (Strong Sell) List on April 16, 2025.

Volatility is back, and while it's normal, fear dominates. Investors are uneasy despite no official correction, as past gains spoiled expectations. Economic uncertainty, rising debt, and inflation risks fuel market anxiety. If Trump acts on lower rates, short-term pain may be inevitable. I'm seizing opportunities, focusing on value and cyclical dividend growth. Buying dips has historically paid off, and I'm betting big on key stocks.

The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies with strong fundamentals. I focus on businesses with resilient models, growth potential, and attractive valuations. Despite headline risks, I believe in their ability to navigate uncertainty and deliver long-term returns. While risks like prolonged trade tensions or economic slowdowns exist, I remain confident in my picks, as they are well-positioned to thrive regardless of short-term market turbulence.

Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.

The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent

The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to non-invasively treat BCC of the skin.

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE